Cystinuria is characterized by a transport failure in the renal tubules for the dibasic aminoacids cystine, lysine, ornithine and arginine. Increased urinary concentrations of these aminoacids ensue and, since cystine is poorly soluble, cystine stones may form. Although cystine stones were described as long ago as 1810 and the condition was recognized as an inborn error of metabolism in 1908, only recently have techniques been available to elucidate the molecular basis for the transport defect.
Cystinuria has an overall incidence of I in 15 000 in the Western world, with pockets of high incidence-for example, in Armenian Jews. Inheritance is autosomal recessive, homozygotes producing an excess of all four aminoacids in the urine and being prone to cystine urolithiasis. Three phenotypes can be distinguished on the basis of their intestinal transport of the same aminoacids. Thus, patients with type I cystinuria, which accounts for 80% of the total, exhibit impaired intestinal transport of all four aminoacids; patients with type II have impaired transport of ornithine, arginine and lysine but normal cystine transport; and patients with type III have normal transport of all four. Whilst these intestinal transport defects have no clinical significance they may provide some insight into the underlying genetic defect.
Two cystine transporters are found in the proximal tubule: one has a high affinity for cystine, is inhibited by ornithine, arginine and lysine and is therefore a cotransporter for these three aminoacids; the second has a low affinity for cystine and is not so inhibited. Under normal conditions half the urinary cystine is reabsorbed by each transporter.
MOLECULAR TRANSPORTER
Recently, a cystinuria disease gene has been identified, encoding the neutral and basic aminoacid transporter variously named NBAT, rBAT NBAT mediates sodium-independent transport of neutral and basic aminoacids and cystine. At least twenty mutations in the NBAT gene have been reported to date resulting in diminution or abolition of aminoacid transport activity. Homozygosity for these mutations co-segregates with cystinuria, with all patients studied so far conforming to the type I phenotype2.
But do mutations in NBAT alone explain the phenotypic spectrum of cystinuria? Labelling with site-specific antibodies suggests that NBAT has only four membranespanning domains3. It is unlikely to function alone as an aminoacid transporter, since most transport proteins have between eight and fourteen transmembrane domains. Studies of rat kidney and jejunal tissue have found NBAT to be associated with a 5OkD protein by one or more disulphide bonds4. Probably this heterodimer is the 'minimal functional unit' of NBAT-mediated aminoacid transport, and mutations in the NBAT-associated protein are likely to account for cystinuria phenotypes II and III.
MANAGEMENT
Medical management attempts to diminish cystine stone formation by the twin strategies of reducing urine cystine concentration and increasing cystine solubility. Since patients' urinary excretion of cystine is constant [at about 3.55 (SD 1.27)mmol/24h] and the solubility of cystine in urine is about 1.5 mmol/L, a daily urine volume of at least three litres should be advocated. Such water therapy may be very successful, even resulting in dissolution of preformed stones. Salt restriction may lower cystine excretion5, so a dietary limit of I mmol/kg per day should be imposed. A small reduction in urinary cystine can also be achieved by a low protein diet, but this is seldom advocated.
Urine alkalinization increases the solubility of cystine and may decrease stone formation. Potassium citrate is preferable to sodium bicarbonate if salt restriction is imposed concurrently. Penicillamine therapy is often useful: its sulphydryl group reacts with cystine to form a penicillamine-cysteine mixed disulphide whose solubility in urine exceeds that of cystine. This treatment may also result in stone dissolution, but it does carry a risk of sideeffects including rashes, thrombocytopenia, neutropenia, proteinuria and nephrotic syndrome. If penicillamine is not tolerated, an alternative with a similar mechanism of action is 2-mercaptopropionylglycine. The use of angiotensin converting enzyme inhibitors bearing sulphydryl groups has been advocated by Perazella and 
